<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2500">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05128617</url>
  </required_header>
  <id_info>
    <org_study_id>2021-004</org_study_id>
    <nct_id>NCT05128617</nct_id>
  </id_info>
  <brief_title>Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study</brief_title>
  <acronym>PROTECT-06</acronym>
  <official_title>Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de cancérologie Strasbourg Europe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université de Strasbourg - Unité de Recherche 3072 - Mitochondries, Stress oxydant, Protection musculaire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de cancérologie Strasbourg Europe</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy treatments such as epirubicin-cyclophosphamid or paclitaxel lead to severe&#xD;
      off-target side effects such as skeletal muscle deconditioning. To date, three different&#xD;
      studies investigated skeletal muscle decontioning in breast cancer patients, through long&#xD;
      term protocols including all chemotherapy cycle treatment, and highlighted both structural&#xD;
      alterations and impaired cellular processes. However, no study is currently availbale on the&#xD;
      acute effect of one single chemotherapy administration in breast cancer patients skeletal&#xD;
      muscle tissue. Our study is therefore dedicated to the investigation of the acute effect of&#xD;
      the first dose administration of both Epuribicin/cyclophosphamide and Paclitaxel&#xD;
      chemotherapies on skeletal muscle of breast cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chemotherapy treatments such as epirubicin-cyclophosphamid or paclitaxel lead to severe&#xD;
      off-target side effects such as skeletal muscle deconditioning. Resulting from a global&#xD;
      perturbation of the muscle homeostasis, skeletal muscle is characterized by both structural&#xD;
      and functional alterations that will translate into a decrease in muscle mass and/or force as&#xD;
      well as an increase in muscle fatigability. These maladaptations result in a reduced quality&#xD;
      of life and an increased treatment-related toxicity, ultimately leading to an increased&#xD;
      mortality risk.To date, three different studies investigated skeletal muscle decontioning in&#xD;
      breast cancer patients, through long term protocols including all chemotherapy cycle&#xD;
      treatment, and highlighted both structural alterations and impaired cellular processes.&#xD;
      However, no study is currently availbale on the acute effect of one single chemotherapy&#xD;
      administration in breast cancer patients skeletal muscle tissue.Our study is therefore&#xD;
      dedicated to the investigation of the acute effect of the first dose administration of both&#xD;
      Epuribicin/cyclophosphamide and Paclitaxel chemotherapies on skeletal muscle of breast cancer&#xD;
      patients. Our study will particularly explore cellular mechanisms of muscle decontioning,&#xD;
      such as protein turnover, mitochondrial homeostasis and fatty infiltrations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Investigate the acute effect of chemotherapy administration on protein turnover cellular processes through vastus lateralis biopsies of breast cancer patients</measure>
    <time_frame>Before and 4 days after the chemotherapy</time_frame>
    <description>Change From Baseline in Western Blots measurements of protein expression levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigate the acute effect of chemotherapy administration on structural alterations</measure>
    <time_frame>Before and 4 days after the chemotherapy</time_frame>
    <description>Change From Baseline in Cross-Sectional Area (CSA) measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigate the acute effect of chemotherapy administration on inflammation</measure>
    <time_frame>Before and 4 days after the chemotherapy</time_frame>
    <description>Change From Baseline in Western Blots measurments of protein expression levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigate the acute effect of chemotherapy administration on mitochondrial homeostasis</measure>
    <time_frame>Before and 4 days after the chemotherapy</time_frame>
    <description>Change From Baseline in Western Blot measurement of protein expression levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigate the acute effect of chemotherapy administration on fatty infiltrations</measure>
    <time_frame>Before and 4 days after the chemotherapy</time_frame>
    <description>Change From Baseline in Western Blot measurement of protein expression levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigate the acute effect of chemotherapy administration on satellite cells</measure>
    <time_frame>Before and 4 days after the chemotherapy</time_frame>
    <description>Change From Baseline in Western Blot measurement of protein expression levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>.Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the skeletal muscle mass</measure>
    <time_frame>Before and 4 days after the chemotherapy</time_frame>
    <description>Change From Baseline in quantity of muscle mass measured by bioelectrical impedance analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the muscle force</measure>
    <time_frame>Before and 4 days after the chemotherapy</time_frame>
    <description>Change From Baseline in the maximal isometric strength of the knee with force transducer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the muscle thickness</measure>
    <time_frame>Before and 4 days after the chemotherapy</time_frame>
    <description>Change From Baseline in ultrasonography measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the muscle fibers angle of pennation</measure>
    <time_frame>Before and 4 days after the chemotherapy</time_frame>
    <description>Change From Baseline in ultrasonography measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the muscle fibers fascicle length</measure>
    <time_frame>Before and 4 days after the chemotherapy</time_frame>
    <description>Change From Baseline in ultrasonography measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the echogenecity</measure>
    <time_frame>Before and 4 days after the chemotherapy</time_frame>
    <description>Change From Baseline in ultrasonography measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the quality of life</measure>
    <time_frame>Before and 4 days after the chemotherapy</time_frame>
    <description>Change From Baseline in FACT-G auto-questionnaire measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the appetite loss</measure>
    <time_frame>Before and 4 days after the chemotherapy</time_frame>
    <description>Change From Baseline in FAACT auto-questionnaire measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the physical activity level</measure>
    <time_frame>Before and 4 days after the chemotherapy</time_frame>
    <description>Change From Baseline in GPAQ auto-questionnaire measurement</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Epirubicin-cyclophosphamide</arm_group_label>
    <description>Woman with early breast cancer receiving a first cycle of epirubicin-cyclphosphamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel</arm_group_label>
    <description>Woman with early breast cancer receiving a first cycle of paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin-cyclophosphamide</intervention_name>
    <description>1 cycle of Epirubicin-cyclophosphamide</description>
    <arm_group_label>Epirubicin-cyclophosphamide</arm_group_label>
    <other_name>Epirubicin-endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>1 cycle of Paclitaxel</description>
    <arm_group_label>Paclitaxel</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      muscle micro-biopsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Woman recieving the first administration of epirubicin-cyclophosphamide (group 1) or&#xD;
        paclitaxel (group 2) for early breast cancer treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Breast cancer (stade I to III)&#xD;
&#xD;
          -  Patient recieving the first administration of epirubicin-cyclophosphamide (group 1) or&#xD;
             paclitaxel (group 2) for early breast cancer treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of cancer&#xD;
&#xD;
          -  Known chronic pathology&#xD;
&#xD;
          -  Pacemaker&#xD;
&#xD;
          -  Contraindication to the evaluation of the physical condition&#xD;
&#xD;
          -  Contraindication to the local anesthesia for the muscle micro-biopsy&#xD;
&#xD;
          -  Breastfeeding or pregnant woman&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valérie SARTORI</last_name>
    <phone>368767223</phone>
    <phone_ext>33</phone_ext>
    <email>v.sartori@icans.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manon VOEGELIN</last_name>
    <phone>368339523</phone>
    <phone_ext>33</phone_ext>
    <email>promotion-rc@icans.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancerologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie SARTORI</last_name>
      <phone>368767223</phone>
      <phone_ext>33</phone_ext>
      <email>v.sartori@icans.eu</email>
    </contact>
    <contact_backup>
      <last_name>Manon VOEGELIN</last_name>
      <phone>368767360</phone>
      <phone_ext>33</phone_ext>
      <email>m.voegelin@icans.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Roland SCHOTT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joris MALLARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elyse HUCTEAU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier PIVOT, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michal KALISH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cathie FISCHBACH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole PFLUMIO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure PIERARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry PETIT, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe TRENSZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Protein turnover</keyword>
  <keyword>Skeletal muscle deconditoning</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Muscle biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

